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Abstract
SARS-CoV-2 become pandemics and there is still a dearth of data about its the
potentially among dermatological patients under biologics. We aimed to assess health
literacy, disease knowledge, treatment dissatisfaction and biologics attitudes toward
COVID-19. We performed a cross-sectional, questionnaire-based survey on 98/105
consecutive dermatological patients treated with biologics—51 suffering from plaque
psoriasis, 22 from atopic dermatitis, and 25 from hidradenitis suppurativa. An ad hoc,
validated questionnaire has 44 items investigating the following domains: knowledge
of COVID-19 related to (a) epidemiology, (b) pathogenesis, (c) clinical symptoms,
(d) preventive measures, and (e) attitudes. Patients data and questionnaires were col-
lected. Despite only 8.1% thought that biologics may increase the risk of COVID-19,
18.4% and 21.4% of the patients were evaluating the possibility to discontinue or
modify the dosage of the current biologic therapy, respectively. Globally, male
patients (P = .001) with higher scholarity level (P = .005) displayed higher knowledge
of COVID-19. Patients with lower DLQI (P = .006), longer disease duration (P = .051)
and lower scholarity (P = .007) have thought to discontinue/modify autonomously
their biologic therapy. At the multivariate logistic regression, only the knowledge of
epidemiology and preventive measures resulted independent predictors of continua-
tion vs discontinuation and modification vs no modification, respectively. Dermatolo-
gists should promote COVID-19 knowledge to prevent biologics disruption.
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1 | INTRODUCTION
Since late December 2019 from Wuhan (Hubei province, People's
Republic of China) a new Coronavirus, also known as SARS-CoV2, has
spread out in neighboring countries leading the Director-General of
the World Health Organization (WHO) to declare pandemics on
March 11, 2020.1,2 Rapidly, Italy has become red-zone with the
highest rate of COVID-19 confirmed, hospitalized and deceased
patients in Europe; thus to handle this massive health emergency sev-
eral medical departments were reconverted in COVID-19-dedicated
or partially dedicated units, dermatology had promoted telemedicine
and maintained face-to-face visits only for urgent patients (ie, mela-
noma surgery) and chronic patients under certain systemic drugs (ie,
biologics and other immunosuppressants).3Paolo Pigatto and Giovanni Damiani contributed equally to this work.
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COVID-19 pandemic has forced everyone to use personal protec-
tive equipment (PPE), such as goggles, N95 masks, double-layers
gloves, and face-shields, and to follow methodically sanitization proto-
cols.2 Hence, health care workers due to too scrupulous and continu-
ous hand-washing and use of preventive measures and protective
equipment could develop hand eczema and related skin disorders.4
Lan and colleagues recruited a sample of 542 health care and in 97%
of them they found a dermatological disorder related to the personal
protective equipment (PPE) and to the preventive measures, mainly
affecting the nasal bridge, the hands, the cheeks and the forehead,
with dryness and desquamation being the most commonly reported
symptoms/signs.5However, mainly occupational aspects have been
investigated so far.
To the best of our knowledge, there is a dearth of data con-
cerning the COVID-19 perceptions of dermatological patients under
biologics, a therapy traditionally associated to an increased risk of
infections.6-9 This aspect is of particular interest since it may affect
the patients' compliance leading to treatment discontinuation or
autonomous modifications.10 Although biologics have revolutionized
the management of chronic dermatological disorders, their interplay
between disease, disease activity, and its pharmacological treatment
is complex and multifaceted, and sometimes drug-related side effects
may occur (ie, airway infections). Side effects are also capable to detri-
ment dermatologist-patients relationship leading to a decreased com-
pliance.11 Furthermore, also inside the dermatological field the
attitude towards biologics are discordant12,13 due to the dearth of
available data.
In these historical and scientific context of uncertainty, in which
hospitals are overwhelmed by COVID-19 emergency and at the same
time are struggled also by the normal routine (acute patients and
chronic ones), we decided to perform a study to assess how COVID-
19 impacts patients under biologics to optimize our daily approach.
2 | MATERIAL AND METHODS
2.1 | Ethical clearance
The protocol study of the present investigation was in-depth
reviewed, respected the ethical principles of seventh Helsinki Declara-
tion and received full ethical clearance by the involved Institutions. All
patients signed a written consent form.
2.2 | Patients selection: inclusion and exclusion
criteria
This cross-sectional, questionnaire-based survey was performed in
February 10, 2020, before the declaration of pandemics, in three pri-
mary referral dermatological centers, IRCCS Galeazzi Orthopedic
Istitute, IRCCS San Donato, both in Milan, and IRCCS San Gallicano in
Rome. All the clinical evaluations were coherent with Italian Society
of Dermatology, Venereology and Sexual Transmitted Diseases
(SIDEMAST) recommendations during COVID-19 pandemics (www.
sidemast.org/blog/coronavirus). Patients scheduled for these days
were consecutively enrolled if they met the eligible criteria.
Patients were enrolled in the present study if meeting the follow-
ing inclusion criteria: (a) aged ≥18 years, (b) diagnosis of plaque psoria-
sis, atopic dermatitis or hidradenitis suppurativa performed by two
independent board-certified dermatologists lasting more than 5 years
ago, (c) with a severity.
• in psoriatic patients: Psoriasis Area Severity Index (PASI)14 ≥10 and
or Disease Activity index for PSoriatic Arthritis” (DAPSA)15 > 14
before starting the systemic treatment and a stable disease (Delta
PASI or Delta DAPSA in two consecutive controls <10%) at the
study baseline;
• in atopic dermatitis patients with Eczema Area and Severity Index
(EASI)16 >22 before starting the systemic treatment and a stable
disease (Delta EASI in two consecutive controls <10%) at the study
baseline;
• in HS patients with Hurley III17 and International Hidradenitis
Suppurativa Severity Score System (IHS4)18 >10 before starting
the systemic treatment and a stable disease (Delta IHS4 in two
consecutive controls <10%) at the study baseline,
(d) under biologics treatment for >1 year.
Patients were excluded if: (a) history or actual diagnosis of psychi-
atric disease, (b) diagnosed degenerative neurological disease
(acquired or congenital), (c) previous chemotherapy, (d) brain tumor,
(e) drug addictions, (f) <1 year of treatment with biologics, (g) <5 years
disease duration.
Remarkably, in these departments patients undergoing a biologi-
cal therapy were affecting only by psoriasis (PsO), or atopic dermatitis
(AD) or hidradenitis suppurativa (HS).
2.3 | Dermatological assessment
After verifying medical history and demographics already recorded in
the database, two board-certified, independent dermatologists clini-
cally assessed the enrolled patients collecting the appropriate severity
scores in compliance with the Italian guidelines.19-23
AD patients were evaluated using Dermatologic Quality of Life
Score (DLQI)23,24 and Eczema Area and Severity Index (EASI). PsO
patients were evaluated using DLQI, PASI and DAPSA (if psoriatic
arthritis was co-diagnosed), whilst HS patients underwent DLQI, Hurley
score, IHS4 and Autoinflammatory Disease Damage Index (ADDI).25
2.4 | Questionnaire development
A validated questionnaire consisting of 44 items was administered to
a cohort of patients with dermatological disorders26 (Supplementary
material 1). The questionnaire was comprised of five sections: the first
assessed the risk perception about the likelihood of becoming
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infected by the SARS-CoV2 and negative attitudes towards the phar-
macological treatment, the second explored the knowledge regarding
the virus, the third the knowledge concerning the clinical symptoms
and manifestations, the fourth preventive measures that can be
implemented against COVID-19 and, finally, the fifth the risk
perception.
2.5 | Statistical analysis
Before commencing any statistical analyses, data were visually
inspected for capturing potential outliers. Descriptive statistics was
performed, by expressing values as means ± SDs. Scores were also
assessed in terms of kurtosis and skewness. Regression analyses were
carried out to shed light on the determinants of the knowledge score.
All statistical analyses were carried out by means of the commercial
software “Statistical Package for Social Sciences” (SPSS version 24 for
Windows, IBM Corporation, Armonk, New York). Graphs were gener-
ated by means of the commercial software MedCalc Statistical Soft-
ware (version 18.11.3, MedCalc Software bvba, Ostend, Belgium,
2019). All figures with P-values less than or equal to .05 were consid-
ered statistically significant.
3 | RESULTS
3.1 | Clinical and demographic data
We interviewed 105 consecutive dermatological patients under bio-
logics and 98 (93.3%) were enrolled, 51 (52.0%) suffering from plaque
psoriasis, 22 (22.4%) from atopic dermatitis, and 25 (25.5%) from
hidradenitis suppurativa. Among psoriatic patients only 27/51 (52.9%)
have also psoriatic arthritis. The mean age in the enrolled patients was
44.36 ± 8.45 years (median 43 years) (PsO: 46.35 ± 9.02, AD:
40 ± 6.90, HS: 44.12 ± 7.18) with a mean disease duration of
17.77 ± 7.19 years (median 17 years) (PsO: 17.35 ± 7.07, AD:
21.55 ± 8.07, HS: 15.28 ± 5.28). Median DLQI was 12 (12.3 ± 2.8)
(PsO: 10.86 ± 2.47, AD: 13.68 ± 2.38, HS: 14.16 ± 2.17). PASI and
DAPSA among psoriatic patients were 2.9 ± 2.2 (median 3) and
6.2 ± 3.7 (median 6). In HS patients IHS4 and ADDI were 7.8 ± 3.4
(median 8) and 2.7 ± 0.8 (median 3) respectively. In AD patients the
EASI was 7.8 ± 2.6 (median 8). From a therapeutic point of view, the
enrolled patients underwent Adalimumab (n = 36, 36.7%), Dupilumab
(n = 22, 22.4%), Etanercept (n = 13, 13.3%), Ustekinumab (n = 10,
10.2%), Ixekizumab (n = 8, 8.2%), Secukinumab (n = 7, 7.1%) and
Certolizumab 2 (2.0%). Further details are shown in Table 1.
3.2 | COVID-19 risk perceptions and relative
attitudes
Scores for each domain and for the overall questionnaire are reported
in Table 2. Noteworthy, no differences among the disease groups
could be found, so the entire sample of dermatological patients was
analyzed in an aggregated manner (Figure 1). SARS-CoV2 infection
worried half of the interviewed patients, in particular 25 (25.6%) were
really worried, 24 (24.5%) moderately worried, 29(29.6%) a little wor-
ried and 20 (20.4%) not worried at all.
Remarkably, 28 (28.6%) patients perceived that their chronic der-
matological disease expose them to a moderate-to-severe risk to con-
tract SARS-CoV2, whereas 17.3% and 54.1% regard it as low or null.
Despite only 8.1% thought that biologics expose them to a moderate
to severe risk to contract SARS-CoV2, 18.4% and 21.4% of the whole
patients declared that they have assessed the possibility to discontinue
or modify the dosage of the current biologic therapy, respectively.
TABLE 1 Main characteristics of the recruited sample
Variable Value
Sociodemographic parameters
Age
Gender
Male
Female
Family history
Scholarity
Primary school
Middle school
High school
University
PhD/master
44.36 ± 8.45 (43)
51 (52.0%)
47 (48.0%)
38 (38.8%)
3 (3.1%)
14 (14.3%)
35 (35.7%)
35 (35.7%)
11 (11.2%)
Disease
Plaque psoriasis
Hidradenitis suppurativa
Atopic dermatitis
51 (52.0%)
25 (25.5%)
22 (22.4%)
Disease severity
Disease duration
DLQI
17.77 ± 7.19 (17)
12.3 ± 2.8 (12)
Psoriasis
PASI
DAPSA
2.9 ± 2.2 (3)
6.2 ± 3.7 (6)
Hidradenitis suppurativa
IHS4
ADDI
7.8 ± 3.4 (8)
2.7 ± 0.8 (3)
Atopic dermatitis
EASI 7.8 ± 2.6 (8)
Biologic therapies
Adalimumab
Dupilumab
Etanercept
Ustekinumab
Ixekizumab
Secukinumab
Certolizumab
36 (36.7%)
22 (22.4%)
13 (13.3%)
10 (10.2%)
8 (8.2%)
7 (7.1%)
2 (2.0%)
Abbreviations: ADDI, Autoinflammatory Disease Damage Index; DAPSA,
Disease Activity Index for PSoriatic Arthritis; DLQI, Dermatologic Life
Quality Score; EASI, Eczema Area and Severity Index; IHS4, International
Hidradenitis Suppurativa Severity Score System; PASI, Psoriasis Area
Severity Index.
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3.3 | Clinical variables influencing COVID-19
questionnaire domains
At the multivariate regression analysis, knowledge regarding the virus
epidemiology was found to correlate with male gender (coefficient
regression 2.59, P = .01) and scholarity level (coefficient regression
1.80, P = .0003).
Knowledge of COVID-19 related pathogenesis was associated with
DLQI (coefficient regression 0.61, P = .0061) and inversely with scholarity
level (coefficient regression −1.03, P = .0620, significantly borderline).
Knowledge concerning clinical symptoms inversely correlated
with DLQI (coefficient regression −0.80, P = .0001), and directly with
scholarity level (coefficient regression 1.40, P = .0058).
Knowledge concerning prevention inversely correlated with DLQI
(coefficient regression −0.33, P = 0.0019) and positively with
scholarity level (coefficient regression 1.00, P = .0002).
COVID-19 related attitudes (drug continuation vs modification/
discontinuation) directly correlated with DLQI (coefficient regression
0.24, P = .0059), disease duration (coefficient regression 0.07,
P = .0513, statistically borderline) and inversely with scholarity (coeffi-
cient regression −0.59, P = .0077).
Globally male patients (coefficient regression 6.97, P = .0003) with
higher scholarity level (coefficient regression 2.57, P = .0049) displayed
higher knowledge of COVID-19. Further details are reported in Table 3.
3.4 | Therapy attitudes and COVID-19
questionnaire
Stratifying according to continuation vs discontinuation and no modi-
fication vs modification in drug dose/schedule, statistically significant
differences in terms of knowledge of COVID-19 related epidemiology,
pathogenesis, clinical symptoms and preventive measures (all, P-value
<.001) were found. Noteworthy, scores were higher in the continua-
tion/no modification group, except for knowledge of COVID-19
related pathogenesis, for which higher scores were reported in the
discontinuation/modification group. No differences could be found in
terms of age, gender distribution, scholarity level, family history,
TABLE 2 Scores of each domain of the questionnaire utilized in the present study
Questionnaire domain
Value Range
Mean SD Minimum Maximum
COVID-19 related epidemiology 39.22 5.00 27 57
COVID-19 related pathogenesis 28.64 5.57 0 42
COVID-19 related clincal symptoms 25.40 5.43 13 37
COVID-19 related prevention 12.12 2.79 6 18
COVID-19 related attitudes 12.39 2.29 9 18
Total COVID-19 related knowledge and attitudes score 117.78 9.41 71 136
F IGURE 1 Knowledge score of COVID-19 related risk perceptions and epidemiology, A; pathogenesis, B; clinical symptoms, C; preventive
measures, D; attitudes, E; and overall score, F; stratified according to the dermatological disorders of the patients recruited (atopic dermatitis.
Hidradenitis suppurativa and plaque psoriasis)
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TABLE 3 Multivariate regression analyses for the scores of each domain and the overall score of the COVID-19 related knowledge and
attitudes questionnaire utilized in the present study
Independent variables Coefficient SE t P rpartial rsemipartial
COVID-19 related knowledge concerning epidemiology
(Constant) 36.78
Age 0.04 0.07 0.52 .6069 .05 .05
Male gender 2.59 0.98 2.63 .0100 .27 .25
Disease −0.70 0.75 −0.93 .3531 −.10 .09
Disease duration −0.12 0.08 −1.55 .1238 −.16 .15
Family history −0.59 0.98 −0.60 .5523 −.06 .06
DLQI −0.21 0.19 −1.10 .2740 −.12 .10
Scholarity 1.80 0.48 3.78 .0003 .37 .35
COVID-19 related pathogenesis
(Constant) 24.61
Age −0.02 0.08 −0.27 .7919 −.03 .03
Male gender 1.81 1.13 1.60 .1129 .17 .15
Disease 0.17 0.86 0.20 .8458 .02 .02
Disease duration −0.03 0.09 −0.30 .7617 −.03 .03
Family history 0.27 1.13 0.24 .8145 .02 .02
DLQI 0.61 0.22 2.81 .0061 .28 .27
Scholarity −1.03 0.55 −1.89 .0620 −.20 .18
COVID-19 related knowledge concerning clinical symptoms
(Constant) 30.82
Age −0.01 0.07 −0.11 .9155 −.01 .01
Male gender 1.69 1.03 1.65 .1022 .17 .15
Disease −0.12 0.78 −0.15 .8786 −.02 .01
Disease duration −0.02 0.08 −0.25 .8061 −.03 .02
Family history −0.46 1.03 −0.45 .6518 −.05 .04
DLQI −0.80 0.20 −4.06 .0001 −.39 .36
Scholarity 1.40 0.50 2.83 .0058 .29 .25
COVID-19 related knowledge of preventive measures
(Constant) 13.58
Age 0.003 0.04 0.10 .9230 .01 .01
Male gender 0.72 0.53 1.34 .1835 .14 .12
Disease −0.32 0.41 −0.80 .4289 −.08 .07
Disease duration −0.02 0.04 −0.55 .5850 −.06 .05
Family history −0.42 0.53 −0.79 .4317 −.08 .07
DLQI −0.33 0.10 −3.19 .0019 −.32 .29
Scholarity 1.00 0.26 3.87 .0002 .38 .35
COVID-19 related attitudes
(Constant) 8.7714
Age 0.01 0.03 0.22 .8288 .02 .02
Male gender 0.16 0.45 0.36 .7217 .04 .03
Disease 0.35 0.34 1.02 .3090 .10 .10
Disease duration 0.072 0.04 1.98 .0513 .20 .18
Family history 0.33 0.45 0.72 .4718 .08 .07
DLQI 0.24 0.09 2.82 .0059 .29 .26
Scholarity −0.59 0.22 −2.73 .0077 −.28 .25
(Continues)
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disease type, disease duration and DLQI score. More details are
shown in Table 4.
At the multivariate logistic regression, only knowledge of COVID-
19 -related epidemiology (OR 0.81 [95%CI 0.67-0.98], P = .0334) and
of COVID-19-related preventive measures (OR 0.54 [95%CI
0.34-0.5], P = .0075) resulted independent predictors (more precisely,
protective factors) of continuation vs discontinuation and modifica-
tion vs no modification, respectively (Table 5).
4 | DISCUSSION
During COVID-19 pandemics 40% of dermatological patients under
biologics have thought to autonomously modify or even discontinue
their therapy.
SARS-CoV2 displayed a special tropism for respiratory epithelium,
thus it may cause respiratory symptoms of different severity spacing
from mild cough to death in 7.2% of the cases in Italy.27,28 Since
COVID-19 pathogenesis involved mainly respiratory airways, patients
with respiratory comorbidities might have higher risk, but at the
moment no data are present to confirm it.29 In literature, both psoria-
sis, atopic dermatitis and hidradenitis suppurativa displayed an higher
risk of respiratory comorbidities; in accord with this evidence 30%
of the interviewed patients thought that their dermatological disease
could increase the SARS-CoV2 infection risk.
Psoriatic patients displayed a baseline airway inflammation,30,31
that may lead to the epidemiologically proven increased risk of asthma,
and chronic obstructive pulmonary disease (COPD).32 AD theory of
“atopic march” gives the pathogenetic rationale to the increased asthma
risk found in atopic patients.33 Then, HS and PsO patients, there is an
high prevalence of smokers and in both disease smoking increase the
severity and flares.34,35 Interestingly, Lippi and colleagues found that
active smoking is not correlated with COVID-19 severity.36
Beside the direct effects of the dermatological disease, the impact
of biologics on SARS-CoV2 infection risk were regarded as negligible
in our patients, in fact only 1 in 10 interviewed patients thought that
biologics may increase their risk to contract COVID-19. Despite only
8.1% thought that biologics expose them to a moderate to severe risk
to contract COVID-19, 18.4% and 21.4% of the whole patients
declared that they have assessed the possibility to discontinue or
modify the dosage of the current biologic therapy, respectively.
Biologics have revolutionized the treatment and management of
chronic dermatological disorders, but they also have increased the rate
of airway infections, especially for psoriasis and hidradenitis
suppurativa.12,13,36,37 Conversely, in a recent meta-analysis Zayed and
colleagues did not find an increased risk of airway infections in AD
patients with asthma undergoing dupilumab.38 No data are still present
about the SARS-CoV2 increased risk of infection in patients undergoing
biologics, but the present literature may justify the therapeutic doubts
occurred in 40% of our patients. Otherwise, transplanted patients
undergoing immunosuppressants, communed by a dysfunctional immune
system seem to not have an increased risk to contract Coronavirus.39,40
Our data suggest that the knowledge about COVID-19 may influ-
ence the therapy discontinuation, in fact COVID-19-related
TABLE 3 (Continued)
Independent variables Coefficient SE t P rpartial rsemipartial
COVID-19 related total knowledge and attitudes score
(Constant) 114.56
Age 0.02 0.13 0.14 .8930 .01 .01
Male gender 6.97 1.84 3.79 .0003 .37 .35
Disease −0.62 1.40 −0.44 .6578 −.05 .04
Disease duration −0.12 0.15 −0.83 .4085 −.09 .08
Family history −0.88 1.84 −0.48 .6335 −.05 .04
DLQI −0.48 0.35 −1.35 .1791 −.14 .13
Scholarity 2.57 0.89 2.89 .0049 .29 .27
Abbreviation: DLQI, Dermatologic Life Quality Index; SE, standard error.
TABLE 4 Univariate analysis showing statistically significant differences between continuation/no modification and discontinuation/
modification groups
Domain Continuation Discontinuation P-value No modification Modification P-value
Epidemiology 40.45 ± 4.31 33.78 ± 4.07 < .001 40.60 ± 4.24 34.19 ± 4.24 < .001
Pathogenesis 27.86 ± 4.33 32.11 ± 8.64 < .001 27.57 ± 4.24 32.57 ± 7.85 < .001
Clinical symptoms 26.70 ± 4.94 19.61 ± 3.46 < .001 26.97 ± 4.64 19.62 ± 4.08 < .001
Preventive measures 12.74 ± 2.66 9.39 ± 1.29 < .001 12.97 ± 2.45 9.00 ± 1.34 < .001
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epidemiology information was a protective factor for biologics dis-
continuation, while the COVID-19-related information on preventive
measures was a protective factor for biologics dosage modification.
Furthermore, scholarity level positive correlates with both preven-
tion and epidemiology domains, but inversely correlates with patho-
genesis domain. To further confirm, COVID-19 related attitudes to
modify/discontinue biologics directly correlated with DLQI, disease
duration and inversely with scholarity. In literature both scholarity
and educational interventions are capable to increase drug adher-
ence and compliance.41-43 Recently, guidelines and vademecum for
patients and dermatologists were produced by the Italian Dermatol-
ogists Society (SIDEMAST), however the dermatological world is still
discordant on use of biologics during COVID-19 pandemics.12,13
Furthermore, also during the overwhelming emergency,44-46 derma-
tologists should dedicate time to discuss COVID-19 insights with
patients undergoing biologics in order to prevent their loss of
compliance.
However, the present study is not without any limitation. The
major shortcoming is represented by the relatively small sample size
employed. Furthermore, the knowledge was limited to pre-pandemic
period. It would be interesting to evaluate knowledge of dermatologi-
cal patients undergoing biologics also in postpandemic period.
5 | CONCLUSION
The knowledge of COVID-19 has a paramount importance in der-
matological patients undergoing biologics and dermatologists
should promote it. Therapy continuation during COVID-19 emer-
gency seems to strictly depend on the quality of information that
patients acquire. Discontinuing or modifying biologic therapy
expose patients to the risk of losing response to a drug previously
useful.
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